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Background: Patients with type 2 diabetes are at a high risk for acute cardiovascular events, which usually arise
from the rupture of a vulnerable coronary lesion characterized by specific morphological plaque features. Thus, the
identification of vulnerable plaques is of utmost clinical importance in patients with type 2 diabetes. However, there
is currently no scoring system available to identify vulnerable lesions based on plaque characteristics. Thus, we
aimed to characterize the diagnostic value of optical coherence tomography (OCT) - derived lesion characteristics
to quantify plaque vulnerability both as individual parameters and when combined to a score in patients with type
2 diabetes.
Methods: OCT was performed in the coronary culprit lesions of 112 patients with type 2 diabetes. The score, which
quantifies plaque vulnerability, was defined as the predicted probability that a lesion is the cause for an acute
coronary syndrome (ACS) (vs. stable angina (SAP)) based on its specific plaque morphology.
Results: Multivariable logistic regression analysis demonstrated that plaque vulnerability was independently
predicted by the minimal fibrous cap thickness overlying a lesion’s lipid core (odds ratio (OR) per 10 μm 0.478,
p = 0.002), the medium lipid arc (OR per 90° 13.997, p < 0.001), the presence of macrophages (OR 4.797, p = 0.015)
and the lipid plaque length (OR 1.290, p = 0.098).
Receiver-operating-characteristics (ROC) analyses demonstrated that these parameters combined to a score
demonstrate an excellent diagnostic efficiency to identify culprit lesions of patients with ACS (vs. SAP, AUC 0.90,
95% CI 0.84-0.96).
Conclusion: This is the first study to present a score to quantify lesion vulnerability in patients with type 2 diabetes.
This score may be a valuable adjunct in decision-making and useful in guiding coronary interventions.
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Patients with type 2 diabetes are at a high risk for acute
cardiovascular events. Acute coronary syndromes (ACS)
usually arise from the rupture of vulnerable coronary le-
sions, which in turn may result in thrombus formation
and the occlusion of a coronary vessel [1]. Recently, sev-
eral characteristics of vulnerable plaques have been sug-
gested in both histopathological as well as clinical
studies [2,3]. These include a thin fibrous cap overlying* Correspondence: mburgmaier@ukaachen.de
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article, unless otherwise stated.a large lipid core, plaque inflammation and the presence
of microchannels [2,4,5]. However, currently there is no
scoring system available to quantify plaque vulnerability,
which could be used to identify lesions at risk to cause
ACS based on individual plaque characteristics. Further-
more, the relative contribution of these morphological
markers to a vulnerable plaque is incompletely understood.
With the emerging use of intravascular imaging mo-
dalities such as virtual histology intravascular ultrasound
(IVUS) and optical coherence tomography (OCT) it is
possible to identify these vulnerable plaque features [6,7].
Compared to IVUS, OCT offers a resolution ~10 times
higher and allows for the first time the visualization oftral Ltd. This is an Open Access article distributed under the terms of the
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tems are missing, the clinical consequence following the
recognition of one or more of these vulnerable plaque fea-
tures by the interventional cardiologist remains uncertain.
Identifying and treating vulnerable lesions is a major
goal particularly in patients with type 2 diabetes, who
are at a high risk for cardiovascular events [9]. Thus, the
identification of vulnerable plaques using an OCT-based
scoring system may have an important impact on choos-
ing the optimal therapeutic strategy particularly in this
high-risk population.
We have recently demonstrated a lower fibrous cap
thickness (FCT), a larger necrotic lipid core and pro-
nounced plaque inflammation in culprit lesions of dia-
betic patients with ACS compared to lesions in patients
with stable angina pectoris (SAP) [5]. Furthermore, re-
cently a prospective study has demonstrated, that ACS
usually arise from the rupture of low grade stenotic le-
sions, which are vulnerable [10]. Taken together, the rec-
ognition and treatment of vulnerable plaques may be an
interesting concept and important particularly in high-
risk patients with type 2 diabetes.
The aim of this study was to characterize the diagnos-
tic value of OCT-derived lesion characteristics to predict
plaque vulnerability both as individual parameters and
when combined to a score.Methods
Study population
112 patients with type 2 diabetes undergoing coronary
angiography due to ACS or SAP and subsequent percu-
taneous coronary intervention of the coronary culprit le-
sion were enrolled in the present investigation at the
Department of Cardiology, University Hospital of the
RWTH Aachen, Germany between June 2011 and February
2014. OCT and quantitative coronary angiography (QCA)
analysis, laboratory testing and clinical history taking
were performed in all patients as previously described
[11,12]. A subset of the diabetic cohort was part of a
former analysis [5].
In the SAP-group lesion identification was based on
the coronary angiogram with an at least intermediate
grade stenosis (>40% on QCA) suitable for coronary
intervention and confirmed by additional information
from electrocardiographic, echocardiographic or MRT-
derived stress testing and/or fractional flow reserve mea-
surements. In patients with ACS the target lesion was
identified due to the evidence of plaque rupture with or
without local thrombus, electrocardiographic findings
and/or echocardiographic wall motion abnormalities. In
case of a TIMI flow grade ≤ II within the target vessel we
performed aspiration thrombectomy to restore TIMI
flow III before intracoronary OCT image acquisition [5].Further inclusion criteria were type 2 diabetes, age
>30 years and written informed consent to the study
protocol. Type 2 diabetes was based on clinical history
of diabetes mellitus, ongoing insulin/oral antidiabetic
therapy and/or an HbA1C-level exceeding 6.5% [5].
Exclusion criteria were left main coronary artery stenosis,
bypass graft lesions, cardiogenic shock, hemodynamic or
rhythmic instability, acute or chronic renal insufficiency
(serum creatinine level >1.5 mg/dl) and pregnancy. We
furthermore excluded severely tortuous and calcified ves-
sels, not allowing the safe advancement of the OCT cath-
eter and the necessity to predilate a target lesion prior to
OCT in order to achieve TIMI flow grade III [5].
The study was approved by the local Ethics Committee
and is in accordance with the Declaration of Helsinki on
ethical principles for medical research involving human
subjects.
OCT image acquisition and analysis
For image acquisition of the target lesion we used the
Frequency-Domain-OCT C7XR system and the Dragon-
Fly catheter (St. Jude Medical Systems, LightLab Imaging
Inc., Westford, Massachusetts, USA) with an automated
pull back device at a rate of 20 mm/s as previously de-
scribed [12]. We achieved blood clearance by the non-
occlusion OCT-technique with injection of isoosmolar
contrast (Iodixanol, GE Healthcare, USA).
Quantitative intraluminal dimensions and plaque morph-
ology were assessed as previously described [5,11,12].
Subsequent offline and pull-back analysis was per-
formed by two independent observers throughout the
entire lesion frame by frame in 0.2 mm intervals, using
the proprietary software provided by LightLab Imaging
and in adaptation to the published consensus for quanti-
tative and qualitative assessment [5,7,13]. In case of dis-
cordant results, a consensus measurement was taken.
Statistical analysis
Statistical analyses were performed with SPSS software
(IBM Corp., Armonk, NY, USA). Categorical variables
were summarized as count (percentage), continuous var-
iables as mean ± standard deviation. To investigate the
diagnostic value of morphologic plaque features to pre-
dict that the lesion is the cause for an ACS, univariable
logistic regression analysis was performed. Plaque pa-
rameters which showed a p-value (Wald statistics) below
0.05 were also studied in a multivariable logistic regres-
sion analysis with consecutive backward selection for
variables which had a p-value below 0.10. In case of a
non-lipid plaque, parameters which were not defined for
non-lipid plaques such as FCT, lipid arc, and lipid
plaque length were set to 0. This is both consistent with
the sign of association of each of these variables with the
dependent variable (i.e. ACS) and may formally be
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with the type of plaque.
The score was calculated based on the multiple regres-
sion equation and represents the predicted probability of
a lesion to be the cause for an ACS (vs. SAP) based on
its specific plaque morphology. Test results are reported
as p-value (p), odds ratio (OR) and corresponding 95%
limits of confidence (CI). Sensitivity, specificity, positive
predictive value (PPV), negative predictive value (NPV)
and optimal cut-off-values were calculated from the re-
ceiver operating characteristic (ROC) curve to identify
culprit lesions of patients with ACS. Values with the
highest Youden-index (sensitivity + specificity - 1) were
identified as optimal cut-off-values. A classification of
the diagnostic efficiency according to the values of the
area under the curve (AUC) was used as described else-
where [14]. A p-value < 0.05 was considered to indicate
statistical significance.
Results
Clinical and lesion characteristics
A total of 112 patients were enrolled in the study and
categorized into a group of 43 patients with ACS and a
group of 69 patients with SAP. The culprit lesion was
examined by OCT in all patients without any peri- or
postprocedural complications. Clinical and lesion char-
acteristics are summarized in Table 1.
Risk factors for plaque vulnerability
To evaluate both clinical and morphological plaque
characteristics as risk factors for ACS, univariable logis-
tic regression analysis has been performed and is
depicted in Table 1. Several morphologic parameters
were identified to be risk factors for ACS including min-
imal (OR per 10 μm 0.39, p < 0.001) and mean (OR per
10 μm 0.57, p = 0.001) FCT overlying a necrotic lipid
core. Furthermore, parameters describing the lipid con-
tent of the lesion such as presence of lipid-rich plaques
(OR 7.09, p < 0.001), mean lipid arc (OR per 90° 18.08,
p < 0.001), lipid plaque length (OR 1.80, p < 0.001) as
well as the lipid volume index (OR per 1000 1.53, p <
0.001) were significant risk factors that the lesion is the
cause of an ACS. Further risk factors included the pres-
ence of macrophages (OR 8.75, p < 0.001) and micro-
channels (OR 2.30, p = 0.036). For further detail, please
refer to Table 1, Figure 1 illustrates OCT-derived fea-
tures of plaque vulnerability.
To investigate which of these risk factors predicted ACS
independently, multivariable logistic regression analysis
has been performed. As demonstrated in Table 2, only
minimal FCT (OR per 10 μm 0.478, p = 0.002), mean lipid
arc (OR per 90° 13.997, p < 0.001) and presence of macro-
phages (OR 4.797, p = 0.015) were independent predictors
for the lesion to be the cause of an ACS. The regressionmodel included also lipid plaque length (OR 1.290), which
was not excluded from the equation due to p = 0.098.
Diagnostic efficiency to predict plaque vulnerability
In order to evaluate the diagnostic efficiency of OCT-
derived parameters to identify culprit lesions of patients
with ACS, ROC statistics has been performed (Figure 2,
Table 3).
Among all independent risk factors for ACS, minimal
FCT (adjusted for the presence of lipid-rich plaques)
had the best diagnostic efficiency (AUC 0.86, optimal
cut-off value 74.5μm (or non-lipid plaque), sensitivity
83.7%, specificity 81.2%, PPV 73.5%, NPV 88.9%).
However, if all four independent parameters were
combined to a score using the equation derived from the
multivariable logistic regression model (Logit(Score) =
-2.401 + 1.568 * (insert 1 if macrophages present; else 0) +
2.639 * (insert medium lipid arc in multiples of 90°) +
0.255 * (insert lipid plaque length in mm) - 0.738 * (insert
minimal FCT in multiples of 10 μm), the diagnostic
efficiency could be improved to an AUC 0.90 (95% CI
0.84-0.96, optimal cut-off value 0.336, sensitivity 79.1%,
specificity 88.4%, PPV 81.0%, NPV 87.1%).
For illustration, this score is used in Figure 3 to quan-
tify the vulnerability of two lesions.
Discussion
The main findings of this study in patients with type 2
diabetes are:
1) Whereas several OCT-derived plaque parameters
are predictors for ACS, only mean lipid arc, lipid
plaque length, presence of macrophages and
minimal FCT were independent predictors.
2) When combined to a score, these four independent
risk factors identify culprit lesions of patients with
ACS with excellent diagnostic efficiency.
Features of the ruptured plaque
Several investigations have described certain lesion mor-
phologies to be found more frequently in patients with
ACS compared to those with SAP [2-4,6]. Thus, histo-
pathological studies have identified a lower FCT (<65 μm)
overlying a large lipid core, a higher incidence of thin-
capped fibroatheromas (TCFA) and an increased macro-
phage infiltration within the plaque [2,15,16] as pivotal
precursors for plaque rupture and concomitant cardiovas-
cular events in ACS patients [17].
With the emerging use of virtual histology IVUS it
was possible to prospectively confirm that ACS usually
arise from the rupture of insignificant lesions with a thin
FCT [10]. The Providing Regional Observations to Study
Predictors of Events in the Coronary Tree (PROSPECT)-
study demonstrated that coronary non-culprit lesions
Table 1 Univariable logistic regression analysis for the lesion to be the cause of an ACS
Parameter ACS (n = 43) SAP (n = 69) OR 95% CI p-value
Clinical:
Age (years) 68.1 ± 9.9 69.6 ± 7.4 0.98 (0.94 - 1.02) ns
Male (n, %) 28 (65.1) 47 (68.1) 0.87 (0.39 - 1.96) ns
BMI (kg/m2) 29.7 ± 5.8 31.5 ± 4.8 0.93 (0.86 - 1.01) 0.081
Hypertension (n, %) 35 (81.4) 60 (87.0) 0.67 (0.23 - 1.86) ns
MAP (mmHg) 93.7 ± 11.5 96.3 ± 13.0 0.98 (0.95 - 1.01) ns
Dyslipidemia (n, %) 26 (60.5) 47 (68.1) 0.72 (0.32 - 1.58) ns
Smoking (n, %) 13 (30.2) 11 (15.9) 2.29 (0.91 - 5.71) 0.077
Family history (n, %) 14 (32.6) 31 (44.9) 0.59 (0.27 - 1.31) ns
Diabetes (years) 12.3 ± 10.5 11.0 ± 9.8 1.01 (0.98 - 1.05) ns
HbA1C (%) 7.78 ± 1.73 7.19 ± 1.45 1.27 (0.98 - 1.65) 0.074
Fasting glukose (mg/dl) 174.8 ± 70.6 164.4 ± 46.7 1.00 (1.00 - 1.01) ns
Total chol (mg/dl) 191.1 ± 43.0 189.8 ± 43.8 1.00 (0.99 - 1.01) ns
LDL-chol (mg/dl) 116.7 ± 36.1 117.0 ± 35.7 1.00 (0.99 - 1.01) ns
HDL-chol (mg/dl) 43.9 ± 14.1 43.9 ± 10.5 1.00 (0.97 - 1.03) ns
Triglyceride (mg/dl) 166.1 ± 92.3 187.1 ± 103.6 1.00 (0.99 - 1.00) ns
CRP (mg/dl) 20.4 ± 30.3 9.1 ± 10.7 1.03 (1.01 - 1.06) 0.016
OCT-derived parameters
MLA (mm2) 1.39 ± 0.76 1.42 ± 0.66 0.94 (0.54 - 1.63) ns
MLD (mm) 1.06 ± 0.26 1.13 ± 0.25 0.30 (0.06 - 1.58) ns
Ref LA (mm2) 6.81 ± 2.36 6.51 ± 2.07 1.06 (0.89 - 1.27) ns
Stenosis length (mm) 9.13 ± 4.22 7.98 ± 5.39 1.05 (0.97 - 1.13) ns
Area stenosis (%) 79.49 ± 7.14 77.34 ± 8.62 1.03 (0.99 - 1.09) ns
Calcified Pl. (n, %) 26 (60.5) 48 (69.6) 0.67 (0.30 - 1.49) ns
Fibrous Pl. (n, %) 33 (76.7) 62 (89.9) 0.37 (0.13 - 1.07) 0.066
Lipid-rich Pl. (n, %) 36 (83.7) 29 (42.0) 7.09 (2.77 - 18.16) <0.001
TCFA n (%) 32 (88.9) 10 (34.5) 15.20 (4.18 - 55.28) <0.001
Non-TCFA (n, %) 3 (8.3) 19 (65.5) 0.05 (0.01 - 0.20) <0.001
Min FCT (10 μm) 5.25 ± 0.94 8.00 ± 2.44 0.39 (0.24 - 0.64) <0.001
Mean FCT (10 μm) 9.75 ± 1.71 12.14 ± 2.44 0.57 (0.41 - 0.79) 0.001
Lipid arc (90°) 1.98 ± 0.39 1.39 ± 0.47 18.08 (4.50 - 72.60) <0.001
LPL (mm) 6.34 ± 2.04 3.58 ± 2.14 1.80 (1.34 - 2.40) <0.001
LVI (per 1000) 11.05 ± 3.39 4.81 ± 3.66 1.53 (1.26 - 1.86) <0.001
Macrophages (n, %) 35 (81.4) 23 (33.3) 8.75 (3.50 - 21.89) <0.001
MC (n %) 25 (58.1) 26 (37.7) 2.30 (1.06 - 5.00) 0.036
The data are presented as mean ± SD or n (%) as well as the odds ratio for the vulnerable plaque with the 95% confidence interval (95% CI).
Abbreviations: ACS acute coronary syndrome, SAP stable angina pectoris, BMI body mass index, MAP mean arterial pressure, Fast. Fasting, LDL low density
lipoprotein, HDL high density lipoprotein, CRP C-reactive protein, OCT optical coherence tomography, MLA minimal lumen area, MLD minimal lumen diameter, Ref.
LA reference luminal area, Pl. plaque, TCFA thin-capped fibroatheroma, FCT fibrous cap thickness, LPL lipid plaque length, LVI lipid volume index, MC microchannel.
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a baseline diameter stenosis of only 32%, but were asso-
ciated with more TCFAs, a greater plaque burden and a
minimal lumen area <4 mm2 using virtual histology
IVUS [10]. On the contrary, when focusing on coronary
culprit lesions, the above and several other studies indi-
cated that lesion severity in culprit lesions is generallygreater than 50% in the majority of ACS cases [10,18-20].
In this context, Tian et al. compared morphologic plaque
characteristics between culprit and non-culprit lesions
and reported that plaque rupture is determined by FCT
and a combination of large plaque burden and luminal
narrowing is a prerequisite for the development of acute
coronary syndromes [19]. These findings are in line with
Figure 1 Representative optical coherence tomography images. A lipid-rich plaque (A) with a lipid arc of 282° is displayed. The right-upper
high-power view (B) shows the fibrous cap measuring 52 μm (small arrows). Macrophages are visible in the right-lower high-power view (C) and
are indicated with dashed arrows.
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TCFAs and a large plaque burden (>70%) as independent
predictors for the occurrence of cardiovascular events in
coronary non-culprit lesions [21]. The Clinical Outcomes
Utilizing Revascularization and Aggressive Drug Evalu-
ation (COURAGE) study revealed that anatomic burdenTable 2 Multivariable logistic regression analysis for the
lesion to be the cause of an ACS
Parameter Odds ratio 95% CI p-value
Minimal FCT (10 μm) 0.478 0.302 - 0.757 0.002
Macrophages (present) 4.797 1.351 - 17.033 0.015
Lipid arc (90°) 13.997 3.186 - 61.494 <0.001
Lipid plaque length (mm) 1.290 0.954 - 1.745 0.098
Abbreviations as in Table 1.of coronary artery disease predicts the risk of death, myo-
cardial infarction and non-ST-elevation ACS [22].
Furthermore, subjects with extensive coronary artery
calcification as derived by computed-tomography were
associated with a rather stable clinical course and pre-
sented a high level of chronic cardiovascular events
compared to patients with mild and moderate coronary
artery calcification, which more frequently presented
with an ACS [23]. This finding strengthens our observa-
tions in the present study as it indicates a potentially
plaque-stabilizing effect of coronary calcification, whereas
soft, predominantly lipid-rich lesions with a thin fibrous
cap may rather tend to rupture due to their lower resist-
ance towards intracoronary forces [23].
Currently there is a paucity of data regarding vulner-
able plaque criteria in patients with type 2 diabetes.
Figure 2 OCT-derived parameters identify lesions of patients with ACS both individually and when combined in a score. ROC curve for
OCT-derived (A) minimal fibrous cap thickness, (B) the mean lipid arc and (C) the lipid plaque length to identify lesions of patients with ACS both
individually and when combined to a score (D). A-C were adjusted for the presence of lipid plaques. The score also including the presence of
macrophages is calculated as described in the text.
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for cardiovascular events and the identification of vul-
nerable plaques and vulnerable plaque features is crucial
in this population. Our own group has previously
demonstrated that diabetic patients with ACS exhibit
more vulnerable plaque characteristics in coronary targetTable 3 ROC-analysis: OCT-derived parameters identify culpri
AUC (95% CI) Cut-off
Macrophages Present
Minimal FCT*LP 0.86 (0.78-0.93) 74.5 μm§
Lipid arc*LP 0.84 (0.76-0.92) 116.73°§
Lipid plaque length*LP 0.82 (0.73-0.91) 3.10 mm§
Score 0.90 (0.84-0.96) 0.336
Abbreviations as in Table 2. AUC area under the curve, Sens Sensitivity, Spec Specific
predictive value, LP lipid plaque, § or non-lipid plaque.lesions compared to diabetics with SAP [5]. Moreover,
we were able to point out an association between a
lower minimal fibrous cap thickness of coronary culprit
lesions to both hemodynamic relevance of a coronary le-
sion as well as to left ventricular dilatation in exclusively
diabetic cohorts [12,24].t lesions of patients with ACS
Sens. Spec. PPV NPV
81.4% 66.7% 60.3% 85.2%
83.7% 81.2% 73.5% 88.9%
79.1% 84.1% 75.6% 86.6%
81.4% 79.7% 71.4% 87.3%
79.1% 88.4% 81.0% 87.1%
ity, CI confidence interval, PPV positive predictive value, NPV negative
Figure 3 Examples for the quantification of lesion vulnerability. Representative images of a vulnerable lipid-rich (A) and a stable calcified
(B) intracoronary plaque as derived from optical coherence tomography are presented with values for the minimal fibrous cap thickness (FCT),
the lipid arc, the lipid plaque length and the presence of macrophages. The score is calculated in these two examples and the absolute probability of
the plaque to be the cause of an ACS (≈quantified plaque vulnerability) is presented.
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gations and adds to the current knowledge by the identi-
fication of vulnerable plaque features in patients with
type 2 diabetes. Specifically, we demonstrate more fre-
quent lipid-rich plaques, a larger necrotic core and a
lower fibrous cap thickness in diabetic patients with
ACS compared to those with SAP.
Quantifying plaque vulnerability
However, the individual and combined power of these
plaque features to quantify plaque vulnerability is in-
completely understood. To the best of our knowledge
this study is first to summarize these previously and in-
dividually established parameters of plaque vulnerability
to a score. Whereas we and others have found non-
plaque derived parameters such as left ventricular dilata-
tion to be predictors for plaque vulnerability [12,24,25],
we confined the present investigation to OCT-derived
plaque parameters to quantify plaque vulnerability.
Using the novel imaging modality OCT with its superior
resolution compared to IVUS, the present analysis was
able to include additional parameters of plaque vulner-
ability, such as macrophage infiltration and the presence
of microchannels [7,8]. Thus, we expand the current
knowledge by demonstrating that among all morpho-
logic plaque parameters studied by OCT, only minimalFCT, presence of macrophages, mean lipid arc and lipid
plaque length are independent predictors of the lesion to
be the cause for an ACS in patients with type 2 diabetes.
Whereas previous studies have also described these pa-
rameters as vulnerable plaque features [10,26], we found
that minimal FCT had the best diagnostic efficiency to
quantify plaque vulnerability among all OCT-derived pa-
rameters investigated.
Furthermore, when combined to a score, these risk
factors offer an excellent diagnostic efficiency to quantify
plaque vulnerability and to identify culprit lesions of dia-
betic patients with ACS.
Using plaque vulnerability to guide coronary interventions
The Fractional Flow Reserve Versus Angiography for
Multivessel Evaluation (FAME)-study had previously
demonstrated a reduction in cardiovascular events if
coronary interventions were guided by fractional flow re-
serve (FFR) rather than angiography alone [27,28]. How-
ever, neither ischemic nor anatomic burden were able to
distinctly identify patients who would benefit from an
invasive revascularization strategy over optimal medical
therapy in COURAGE [22]. Thus, these data emphasize
the importance of optimal medical therapy on the one
hand and also – more importantly – the need for alter-
native diagnostic and therapeutic strategies to guide and
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this regard, a score to quantify the vulnerability of a cor-
onary lesion might be of interest.
Using the OCT-risk score for plaque vulnerability pre-
sented in this study it may be possible to unmask those
lesions at risk to cause an ACS in high-risk patients with
type 2 diabetes. Therefore, our findings possibly indicate
that OCT may be essential for guiding the clinical deci-
sion for revascularization beyond angiographic or hemo-
dynamic lesion severity. As this novel score focuses on
the overall and combined impact of single features of
plaque vulnerability it may have the potential to be a valu-
able and convenient tool for clinical risk-stratification and
clinical decision-making. Moreover, this score may sup-
port and extend the clinical indication spectrum for OCT
and in selected cases may be an alternative and/or com-
plement to FFR, which has hitherto been the gold-
standard for evaluating the PCI indication [12,27,28].
This applies in particular to lesions in which the rele-
vance of the FFR technique is either limited, such as
in case of serial stenoses or challenging anatomic sites,
like left main or bifurcation lesions, or if FFR measure-
ments lack clear hemodynamic significance despite
advanced angiographic stenosis severity or persistent
clinical symptoms.
Thus, this score may help to guide PCI in lesions in
which FFR measurements are either not reliable or applic-
able. However, if FFR assessment displays hemodynamic
relevance of a coronary stenosis, PCI should be performed
irrespective of the value of our score.
Future studies are warranted to evaluate this score in
prospective trials and to determine if coronary interven-
tions guided by this score reduce cardiovascular morbid-
ity and mortality in patients with type 2 diabetes. The
present investigation may be the basis for further clinical
studies to validate this score in larger diabetic as well as
non-diabetic cohorts.
Limitations
Although the current study is hitherto the largest OCT-
study in an exclusively diabetic cohort, the relatively
small sample size limits the precision of the regression
coefficients.
Second, large randomized studies are required to
evaluate whether our score may actually help to reduce
cardiovascular morbidity and mortality in high-risk pa-
tients with type 2 diabetes.
Third, as we have excluded patients with hemodynamic
instability or cardiogenic shock our data may only partially
reflect the true incidence of plaque ruptures and specific
plaque features in ACS patients.
Finally, as this is a study in an exclusively diabetic co-
hort, future studies are needed to determine if this score
can also be applied to patients without diabetes.Conclusion
According to the findings of this OCT-study we con-
clude that in patients with type 2 diabetes minimal FCT,
presence of macrophages, mean lipid arc and lipid
plaque length are independent morphologic predictors
for acute coronary events. When combined to a score
these parameters have an excellent diagnostic efficiency
to quantify plaque vulnerability. Future interventional
studies are warranted to determine if this score may help
to reduce cardiovascular morbidity and mortality in
high-risk patients with type 2 diabetes.
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